Press Releases

02.11.2020

XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC

01.31.2020

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)

01.28.2020

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS

01.23.2020

Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults

01.23.2020

Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)

01.14.2020

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

01.13.2020

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc.

01.13.2020

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

01.07.2020

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

01.06.2020

BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

12.23.2019

Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program

12.23.2019

BioInvent announces selection of second target and extension of the research collaboration and license agreement with Pfizer Inc.